Welcome to our dedicated page for Alterity Therapeutics SEC filings (Ticker: PRNAD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Alterity Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Alterity Therapeutics's regulatory disclosures and financial reporting.
ALTERITY THERAPEUTICS LTD director Julian Michael Babarczy, through Vaucluse Investment Holdings Pty Ltd <Jigsaw Investment A/C>, received a grant of unlisted options on June 15, 2026. The award covers 2,000,000 options, each exercisable into one ordinary share at an exercise price of 1.0000 per share, expiring on June 15, 2031. This is a compensation-related acquisition of derivative securities, not an open-market share purchase or sale, and leaves 2,000,000 options held indirectly following the transaction.
ALTERITY THERAPEUTICS LTD director Julian Michael Babarczy, through Vaucluse Investment Holdings Pty Ltd <Jigsaw Investment A/C>, received a grant of unlisted options on June 15, 2026. The award covers 2,000,000 options, each exercisable into one ordinary share at an exercise price of 1.0000 per share, expiring on June 15, 2031. This is a compensation-related acquisition of derivative securities, not an open-market share purchase or sale, and leaves 2,000,000 options held indirectly following the transaction.
ALTERITY THERAPEUTICS LTD director Lawrence Bernard Gozlan, through Montoya Pty Ltd <Buttercup A/C>, received a grant of derivative securities. The award consists of 1,000,000 listed options, each exercisable into one ordinary share at an exercise price of $1.0000 per share.
The options were granted on 15 June 2026 and expire on 15 June 2031. Following this grant, the indirect holdings reported in this listed option position total 1,000,000 options.
ALTERITY THERAPEUTICS LTD director Lawrence Bernard Gozlan, through Montoya Pty Ltd <Buttercup A/C>, received a grant of derivative securities. The award consists of 1,000,000 listed options, each exercisable into one ordinary share at an exercise price of $1.0000 per share.
The options were granted on 15 June 2026 and expire on 15 June 2031. Following this grant, the indirect holdings reported in this listed option position total 1,000,000 options.